One of the mechanisms of gtucocorticoid-induced hypertension has been thought to be the enhancement of vascular responsiveness to vasoconstrictors. In this regard, the effects of glucocorticoids on inositol trisphosphate production in vascular smooth muscle cells were studied. Angiotensin II and arginine vasopressin transiently increased inositol trisphosphate formation in a dose-dependent manner. Pretreatment with dexamethasone for 48 hours shifted the doseresponse curves of angiotensin II-and arginine vasopressin-induced inositol trisphosphate production to the left, that is, it significantly reduced the half-maximal effective concentrations of angiotensin II (from 25 nM to 5 nM) and arginine vasopressin (from 50 nM to 25 nM). These effects of dexamethasone required a minimum of 12 hours of incubation; maximum effect was observed after 24 hours of treatment A glucocorticoid antagonist, RU 38486, completely blocked these effects. To elucidate the interaction with prostaglandin, we used indomethacin, a potent inhibitor of prostaglandin synthesis. Treatment with indomethacin shifted the dose-response curves of angiotensin II-and arginine vasopressin-induced inositol trisphosphate production to the left. However, this shift was less than that seen after dexamethasone treatment Indomethacin alone did not completely reproduce dexamethasone effects, and no additive effect between indomethacin and dexamethasone was observed. These results suggest, at least in part but not entirely, that the effects of dexamethasone depended on prostaglandin synthesis inhibition. We concluded that glucocorticoids altered the responsiveness of vascular smooth muscle cells to angiotensin II and arginine vasopressin through a glucocorticoid-specific receptor. These actions strongly support the mechanism by which the glucocorticoid induced hypertension through the increased sensitivity to vasoconstrictors. {Hypertension 1992;19:109-115) G lucocorticoids are known to be involved in regulation of blood pressure and also to induce hypertension. 1 -2 Although the exact mechanisms of glucocorticoid-induced hypertension are poorly understood, enhancement of vascular responsiveness has been considered one of the major contributing factors.
G lucocorticoids are known to be involved in regulation of blood pressure and also to induce hypertension.
1 -2 Although the exact mechanisms of glucocorticoid-induced hypertension are poorly understood, enhancement of vascular responsiveness has been considered one of the major contributing factors. 3 - 4 Previously, we demonstrated that the pressor response to norepinephrine is enhanced in rats with glucocorticoid-induced hypertension. 5 Similar results were obtained from the patients with Cushing's syndrome. 6 Other studies also supported the notion that glucocorticoids increase vascular responsiveness. 7 - 8 However, there are few studies elucidating the increased vascular responsiveness by glucocorticoids in vitro.
In this study, our intent was to clarify the mechanisms of glucocorticoid-induced hypertension at the cellular level, that is, we investigated the effects of glucocorticoids on vascular responsiveness by using cultured vascular smooth muscle cells (VSMCs). Because VSMC contraction can be induced by cytosolic calcium elevation mediated by inositol phosphate-specific phospholipase C activation, 9 -10 we determined the effect of glucocorticoid treatment on vasoconstrictor-induced inositol trisphosphate (IP 3 ) production in VSMCs.
To our knowledge, the present study provides the first direct evidence that glucocorticoids alter the vascular responsiveness to angiotensin II (Ang II) and arginine vasopressin (AVP) by modulating IP 3 production. Also, these results strongly suggest that glucocorticoid treatment would increase sensitivity to Ang II and AVP. oxide (DMSO), and bovine serum albumin (BSA) were purchased from Sigma Chemical Co., St. Louis, Mo. Indomethacin, norepinephrine, perchloric acid, and KOH were obtained from Wako Pure Chemical Industries, Ltd., Osaka, Japan. Ang n, AVP, and [Sar ', Ala 8 ]-Ang II were from the Peptide Institute, Osaka, Japan. Fetal calf serum (FCS) was purchased from Gibco Laboratories, Grand Island, N.Y. Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS), and Hanks' solution were obtained from Nissui Pharmaceutical Co., Ltd., Tokyo. The IP 3 assay kit (TRK 1000) was purchased from Amersham International, Ltd., Buckinghamshire, England. RU 38486, a glucocorticoid antagonist, was kindly provided by Roussel Uclaf, Paris.
Cell Culture
VSMCs were prepared from the thoracic aorta of 6-week-old Wistar-Kyoto rats by an enzyme method using a modification of the technique described by Smith and Brock. 11 Briefly, the thoracic aorta was dissected from the surrounding tissues. After the adipose tissues around the aorta were removed under sterile conditions, the aorta was incubated in Hanks' solution containing 1 mg/ml collagenase and 3.3 units/ml elastase at 37°C for 30 minutes. After enzyme treatment, vascular tissues were cut into small pieces and further digested in Hanks' solution containing 1 mg/ml collagenase and 10 units/ml elastase at 37°C for 1.5-2 hours. The isolated cells were washed and then were suspended in DMEM containing 10% FCS, penicillin at 100 units/ml, and streptomycin at 100 yxg/ml. The cells were plated in 35-mm culture dishes. The cultures were kept at 37°C in a humid atmosphere consisting of 5% CO 2 in air, and the medium was changed every 3 or 4 days. After the cells reached confluence, the medium was changed to culture media containing various doses of dexamethasone or vehicle (0.1% DMSO) as a control, for 48 hours before the experiments. Cells between the third to tenth passage were used for the experiments.
Measurement of 1,4,5-Inositol Trisphosphate Production in Vascular Smooth Muscle Cells
Production of 1,4,5-EP 3 in VSMCs was measured with a radioimmunoassay kit (TRK 1000). Confluent VSMCs were trypsinized (0.25% trypsin, 0.03% EDTA in PBS) and then were suspended in cold PBS containing 1 mg/ml BSA. After the VSMCs were rewarmed at 37°C for 10 minutes, 0.01 volume of various doses of vasoconstrictors was added and vortexed. After a designated time for each study, 0.2 volume ice-cold 20% perchloric acid was added, and the mixture was kept on ice for 20 minutes. Protein was removed by centrifugation at 2,000g for 15 minutes at 4°C; the supernatant was titrated to pH 7.5 with ION KOH and was kept on ice for 60 minutes. After removal of insoluble KCIO* by centrifugation, 100 fi\ supernatant was mixed with the assay buffer containing 0.1 M Tris buffer, 4 mM EDTA, and 4 mg/ml BSA (pH 9.0). Then 100 n\ tracer (D-myo- 
Protein Determination
The protein levels in VSMCs were determined by the method of Lowry et al, 12 using BSA as a standard.
Statistical Analysis
The results were expressed as the mean±SEM, and the statistical significance was assessed by Student's / test. Values of /?<0.05 were considered to be significant.
Results

Cell Culture
The cells prepared from the thoracic aorta of Wistar-Kyoto rats had typical smooth muscle morphology including the presence of hills and valleys seen under a phase-contrast microscope. Additionally, we demonstrated the presence of smooth muscle actin by indirect immunofluorescence microscopy. 13 
Effects of Dexamethasone on Angiotensin H-Induced Inositol Trisphosphate Production
Effect of dexamethasone on dose-response curve of angiotensin H-induced inositol trisphosphate production. The basal intracellular IP 3 content measured by our method was 5.8 ±0.3 pM/10* cells. When VSMCs were stimulated by Ang II, IP 3 rapidly increased and reached the maximal level 10 seconds after the addition of Ang II, then declined to the basal level within 1 minute. The maximal IP 3 level induced by 10 nM Ang II stimulation was 252.0±10.0% of the basal IP 3 ( Figure 1 ). These results were consistent with earlier observations. addition of Ang II. Ang II increased IP 3 production in a dose-response manner with the half-maximal and maximal effects found at 25 nM Ang II and 1 uM Ang II, respectively. The maximal level of Ang Il-induced IP 3 production was 404.5±9.3% of the basal EP 3 . The treatment with dexamethasone for 48 hours shifted the dose-response curve to the left. The half-maximal effect was found at 5 nM Ang II, significantly reduced (p<0.01), but the maximal level of Ang Il-induced IP 3 production was the same as that of the control, 412.0 ±9.0% of the basal IP 3 level.
Angiotensin II increased inositol trisphosphate production through its specific receptor. To determine whether Ang Il-induced IP 3 production was mediated by its specific receptor, VSMCs were treated , Ala'J-Ang II. One micromolar [Sar^Ala^-Ang II alone had no effect on the basal intracellular IP 3 level in control and dexamethasone-treated cells. The IP 3 production stimulated by 10 nM Ang II was completely blocked by 1 uM [Sar'^Ala^-Ang II, irrespective of the presence of dexamethasone. These results showed that Ang II induced EP 3 production through its specific receptor (Figure 3) .
Effects of different concentrations of dexamethasone on inositol trisphosphate production stimulated by angiotensin II. VSMCs treated with different concentrations of dexamethasone exhibited a dose-related increase in the IP 3 response to 10 nM Ang II. The increased IP 3 response became apparent as low as 10 nM dexamethasone and became maximal at 1 uM dexamethasone (Figure 4) .
Effect of dexamethasone was through the glucocorticoid-specific receptor. To demonstrate whether the effect of dexamethasone was through the intracellular glucocorticoid receptor, VSMCs were incubated with 10 /xM RU 38486, a glucocorticoid receptorspecific antagonist, with or without 1 /iM dexamethasone for 48 hours. Although RU 38486 alone had no effect on basal and Ang Il-induced IP 3 levels, it completely blocked the effect of 1 uM dexamethasone ( Figure 5 ). These results suggested that this dexamethasone effect was through the glucocorticoid-specific receptor.
Time course of the effect of dexamethasone on Ang Il-induced inositol trisphosphate production. VSMCs were treated with 1 uM dexamethasone for various periods of time before Ang II stimulation. An increased IP 3 response was detected as early as 12 hours, and the maximum effect was observed at 24 hours. This effect of dexamethasone was still recognized after 72 hours of treatment ( Figure 6 ). alone did not completely reproduce the dexamethasone effect on Ang II-induced IP 3 production even at higher concentrations (data not shown). Moreover, no additive effect between indomethacin and dexamethasone was observed. These results suggest that, at least in part, the effect of dexamethasone on Ang II-stimulated IP 3 production is dependent on inhibition of prostaglandin synthesis.
Effects of Dexamethasone on Arginine VasopressinInduced Inositol Trisphosphate Production Effect of dexamethasone on dose-response curve of arginine vasopressin-induced inositol trisphosphate
production. AVP stimulated IP 3 production in a manner very similar to that of Ang II. IP 3 increased rapidly, reached the maximal level in 10 seconds, and declined to the basal level within 1 minute. However, the maximal IP3 level induced by stimulation with 100 nM AVP was 251.9±5.2% of the basal IP 3 level, which was significantly lower than that induced by the same concentration of Ang II and was consistent with the results of previous studies. 15 The treatment with 1 /xM dexamethasone for 48 hours did not affect the time course of IP 3 production after AVP stimulation (data not shown). However, in dexamethasone-treated cells, 100 nM AVP induced a significantly higher (/><0.05) EP 3 level at 10 seconds than in untreated cells (306.8±6.4% versus 251.9±5.2%). Figure 8 shows the dose-response curve of AVPinduced IP 3 production at 10 seconds. AVP induced the increased IP 3 in a dose-response manner with the half-maximal and maximal effects found at 50 nM and 1 fiM AVP, respectively. The maximal level of AVP-induced IP 3 production was 305.8+8.2% of the basal IP 3 . The treatment with dexamethasone for 48 hours shifted this dose-response curve to the left. The half-maximal effect was found at 25 nM AVP, significantly reduced (p<0.05), but the maximal level of AVP-induced IP 3 production was the same as that of the control, 310.7±7.5% of the basal IP 3 level. The effect of dexamethasone on AVP-induced IP 3 production was significantly more modest than that on Angn.
Other effects of dexamethasone on arginine vasopressin-induced inositol trisphosphate production. Other effects of dexamethasone on AVP-induced IP 3 production were very similar to the effects on Ang II-induced production. The increased IP 3 response was apparent as low as 10 nM dexamethasone and was maximal at 1 nM dexamethasone. Although 10 fiM RU 38486 alone had no effect on the basal and AVP-induced IP 3 levels, it completely blocked the effect of 1 /AM dexamethasone. An increased IP 3 response was detected as early as after 12 hours of treatment with dexamethasone, and the maximum effect was observed at 24 hours. This effect of dexamethasone was still apparent after 72 hours of treatment. The treatment with 1 fiM indomethacin for 48 hours shifted the dose-response curve of AVP-induced IP 3 production to the left. However, this shift was not as marked as that seen after treatment with 1 /xM dexamethasone. Moreover, no additive effect between indomethacin and dexamethasone was observed (Table 1) . Indomethacin alone did not completely reproduce the effect of dexamethasone on AVP-induced IP 3 production even at higher concentrations.
Effects of dexamethasone on norepinephrine-induced inositol trisphosphate production. Addition of norepinephrine increased the amount of IP 3 within 10 seconds, reaching a peak value at 30 seconds, and then falling to the level before the addition of norepinephrine within 2 minutes. The IP 3 level 30 seconds after the addition of 10 /xM norepinephrine was 132.0±6.5% of the basal IP 3 level. The treatment with 1 /xM dexamethasone for 48 hours did not have any effect on norepinephrine-induced IP 3 production and metabolism. We did not observe any effect of dexamethasone on norepinephrine-induced EP 3 production; it was seen only with addition of Ang II and AVP.
Effects of dexamethasone on cell number and cell protein. Dexamethasone had no significant effects on cell number and cell protein in VSMCs incubated for 48 hours, as compared with the control.
Discussion
In the present study, we first demonstrated the direct effects of glucocorticoids on VSMCs, which could potentially explain how glucocorticoids induce hypertension. Glucocorticoids altered the responsiveness of VSMCs to Ang II and AVP through the glucocorticoid-specific receptor. Treatment with dexamethasone shifted the dose-response curve of Ang IT-and AVP-induced IP 3 production to the left, strongly suggesting increased sensitivity to Ang II and AVP after dexamethasone treatment. These effects were partially dependent on inhibition of prostaglandin synthesis. This finding is very meaningful in terms of demonstrating one of the mechanisms of glucocorticoid-induced hypertension at the cellular level.
The precise mechanisms of the effects of glucocorticoids on these results are still unclear. The potent inhibition of prostaglandin synthesis by glucocorticoids is one of them, as mentioned earlier. However, the results of this study show that glucocorticoids may exert their effects in other ways. Both Ang II and AVP bind to their own specific receptors on VSMCs and produce two second messenger molecules, IP 3 and diacylglycerol.
916
- 17 Dexamethasone shifted the dose-response curves of IP 3 production stimulated by Ang II and AVP to the left; the most plausible explanation is that dexamethasone increases the affinity but not the number of Ang n and AVP receptors. However, since there is little information about Ang II or AVP receptor affinity increased by glucocorticoids, it is less likely that the changes in receptor affinity induce the shift. An alternative explanation may reside in changes at the level of guanine nucleotide binding (G) protein since glucocorticoids are reported to modulate the function of G protein.
"
21 This notion is supported by the experimental evidence that the action of dexamethasone appeared after 12 hours of incubation. This relatively long duration could account for the involvement of G protein with respect to protein synthesis. However, at present, modulation of G protein in receptor affinity or its participation in phospholipase C activation cannot be made because of the paucity of definitive information concerning the specificity of G protein involvement in agonist-induced transmembrane signaling.
Another possible factor that could explain our data is the interactions with prostaglandin synthesis. In our previous studies, 5 - 22 we showed that prostaglandins are modulators of vascular reactivity and that glucocorticoids inhibit prostaglandin synthesis resulting in enhancement of vascular reactivity. Furthermore, studies using an antiglucocorticoid, RU 38486, showed that diminished stimulation of vascular prostacyclin synthesis might contribute to vascular hyperreactivity in glucocorticoid-induced hypertension. 4 -23 In our present study, the treatment with indomethacin shifted the dose-response curves of Ang II-and AVP-induced IP3 production to the left. However, these alterations in responsiveness were not as pronounced as that seen after treatment with dexamethasone. When indomethacin and dexamethasone were administered simultaneously, the dose-response curves of Ang II-and AVP-induced IP3 production were identical with that obtained after dexamethasone treatment alone. From these results, it is possible that these dexamethasone actions were partially dependent on inhibition of prostaglandin synthesis. Moreover, the basal concentrations of prostaglandins in cultured VSMCs are reported to be relatively low, 24 which might explain why dexamethasone had no effect on the basal intracellular IP 3 concentration in the present study. In addition, calcium-mobilizing vasoconstrictors are shown to potently induce prostaglandin release, 24 suggesting that dexamethasone might suppress such vasoconstrictor-induced prostaglandin release. However, since both dexamethasone and indomethacin inhibit all kinds of prostaglandin synthesis, we cannot exclude the possibility of involvement of prostaglandin. Accurately, our current study showed that the effects of dexamethasone were not fully explained by the inhibition of cyclooxygenase activity alone. Nevertheless, a recent study on renal mesangial cells revealed that prostaglandin E2 attenuated IP 3 production in response to Ang II and AVP, thus indicating that indomethacin could restore the Ang II-and AVP-induced IP 3 content. 25 The role of prostaglandin synthesis during dexamethasone treatment in EP 3 production induced by vasoconstrictors remains indistinct, and further study will be needed.
Interestingly, dexamethasone failed to have any effect on norepinephrine-induced IP 3 production. Norepinephrine, like Ang II and AVP, is a potent vasoconstrictor. The involvement of prostaglandin might be related to this finding, since Hassid and Williams 24 demonstrated that Ang II and AVP stimulated prostaglandin synthesis in VSMCs, whereas norepinephrine did not. Previously, we reported that Ang II and AVP but not norepinephrine increased collagen synthesis in the same culture of VSMCs as used in the present study. 26 Taken together, these results can suggest that the connection of a r receptor of VSMCs with G protein and/or the effects of prostaglandin synthesis might be different from that of Ang n and AVP.
Another important finding in the present study is that this glucocorticoid effect was through an intracellular glucocorticoid-specific receptor. The steroid derivative RU 38486 has antiglucocorticoid activity and high binding affinity for a cytosolic steroid receptor. 27 The treatment with RU 38486 had no effect on basal or Ang II-or AVP-induced IP 3 production itself. However, the effects of dexamethasone on Ang II-and AVP-induced IP 3 production were completely blocked by RU 38486. It suggested that these dexamethasone effects were through glucocorticoidspecific receptors.
In conclusion, we first demonstrated that glucocorticoids altered the responsiveness to Ang II-and AVP-induced IP 3 production through its specific receptor, which strongly suggested increased sensitivity to Ang II and AVP after the glucocorticoid treatment. Moreover, these effects were partially dependent on inhibition of prostaglandin synthesis. This evidence was to make clear, by using VSMCs, the mechanisms of vascular hypersensitrvity in glucocorticoid-induced hypertension.
